Related Experiment Videos
[Changes of lymphocyte subpopulation in advanced renal cell carcinoma patients with marked response to
Y Kobayashi1, M Yuzawa, Y Sugaya
1Department of Urology, Jichi Medical School.
Abstract:
At present, no sufficient therapy for advanced renal cell carcinoma is available. Interferon (IFN) therapy has been used to treat renal cell carcinoma, but the efficacy of it is low, with response rate being only about 20%. We experienced two patients with advanced renal cell carcinoma had marked response to IFN-alpha therapy in proximity effect. Using monoclonal anti-bodies of each subset of lymphocytes, the peripheral blood lymphocytes (PBL) in these patients were evaluated by two color flow-cytometry. And these results and clinical course were assessed. The lymphocyte subpopulation that change of clinical course is been similar to in these patients were Tc (CD11b-CD8+), TSI (leu8+ CD4+), ATS/C (CD8+ HLA-DR+) and ATH/SI (CD4+ HLA-DR+). And the pretherapeutic immunological status of these patients was characterized by significantly increased CD4+/CD8+ and TH/TS ratio. In conclusion, the clinical response of advanced renal cell carcinoma to IFN therapy might be found if CD4+/CD8+ and TH/TS ratio are increased at pretherapeutic immunological status. In addition, assessment of TSI, TC, ATH/SI, and ATS/C, as immune parameters for monitoring the actual immune status of patient is found to be necessary part of immunotherapy.
Insights
Advanced renal cell carcinoma patients showed significant response to Interferon-alpha therapy. Pre-treatment immune status, including elevated CD4+/CD8+ and TH/TS ratios, predicted positive outcomes in this immunotherapy study.
Area of Science:
- Oncology
- Immunology
- Biotherapy
Background:
- Advanced renal cell carcinoma lacks sufficient effective therapies.
- Interferon (IFN) therapy shows limited efficacy (approx. 20% response rate) for renal cell carcinoma.
Observation:
- Two patients with advanced renal cell carcinoma experienced marked response to IFN-alpha therapy.
- Peripheral blood lymphocytes (PBL) were analyzed using two-color flow cytometry.
- Specific lymphocyte subpopulations (Tc, TSI, ATS/C, ATH/SI) correlated with clinical course changes.
Findings:
- Pre-therapeutic immunological status was characterized by significantly increased CD4+/CD8+ and TH/TS ratios.
- Immune parameters like TSI, TC, ATH/SI, and ATS/C were identified as crucial for monitoring immunotherapy effectiveness.
Implications:
- Predicting clinical response to IFN therapy in advanced renal cell carcinoma may be possible by assessing pre-treatment CD4+/CD8+ and TH/TS ratios.
- Monitoring specific immune parameters is essential for optimizing immunotherapy strategies in renal cell carcinoma patients.